Does VELIPARIB Cause Malignant neoplasm progression? 13 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Malignant neoplasm progression have been filed in association with VELIPARIB. This represents 3.3% of all adverse event reports for VELIPARIB.
13
Reports of Malignant neoplasm progression with VELIPARIB
3.3%
of all VELIPARIB reports
4
Deaths
1
Hospitalizations
How Dangerous Is Malignant neoplasm progression From VELIPARIB?
Of the 13 reports, 4 (30.8%) resulted in death, 1 (7.7%) required hospitalization, and 1 (7.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VELIPARIB. However, 13 reports have been filed with the FAERS database.
What Other Side Effects Does VELIPARIB Cause?
Neutrophil count decreased (124)
Anaemia (118)
White blood cell count decreased (94)
Febrile neutropenia (76)
Platelet count decreased (70)
Hypertension (57)
Nausea (46)
Hyponatraemia (38)
Vomiting (36)
Hypokalaemia (31)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which VELIPARIB Alternatives Have Lower Malignant neoplasm progression Risk?
VELIPARIB vs VEMURAFENIB
VELIPARIB vs VENETOCLAX
VELIPARIB vs VENLAFAXINE
VELIPARIB vs VENTAVIS
VELIPARIB vs VENTOLIN